UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 27, 2022
Commission File Number: 001-39387
Renalytix plc
(Translation of registrant’s name into English)
Finsgate
5-7 Cranwood Street
London EC1V 9EE
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On June 23, 2022 Renalytix plc issued a press release announcing the company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open.
EXHIBIT INDEX
Exhibit |
|
Description |
|
|
|
99.1 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RENALYTIX PLC |
||
|
|
|
By: |
|
/s/ James McCullough |
|
|
James McCullough |
|
|
Chief Executive Officer |
Date: June 27, 2022
Exhibit 99.1
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
NEW YORK and SALT LAKE CITY, June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID: 1546327
Webcast Registration link: https://edge.media-server.com/mmc/p/y3zwhkuk
For further information, please contact:
Renalytix plc |
www.renalytix.com |
||
James McCullough, CEO |
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
||
Alex Price / Nicholas Moore |
|
||
|
|
||
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
||
Gary Clarence / Daniel Adams |
|
||
|
|
||
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
||
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.